3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
108
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
17
Sarcoma
16
Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Brain Neoplasms
5
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Leiomyosarcoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Advanced Breast Cancer
2
Interventions
Trastuzumab
4
Capecitabine
4
tucatinib
3
fludarabine
2
Spinal Puncture
2
Radiotherapy
2
Nivolumab
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
mafosfamide
1
gadopiclenol
1
gadobutrol
1
fludarabine phosphate
1
eribulin
1
avelumab
1
aldesleukin
1
WP 744
1
Topotecan
1
Temozolomide
1
Specimen Handling
1
Rituximab
1
Phlebotomy
1
Mesna
1
Interleukin-2
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Meningeal Neoplasms
×
eribulin
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled